Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Eksborg S.) > (2010-2014) > Patients with rheum...

Details
MARC

Augustsson, J (author)

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)

Article/chapterEnglish2010

Publisher, publication year, extent ...

2009-05-25
BMJ,2010

Numbers

LIBRIS-ID:oai:prod.swepub.kib.ki.se:119722691
http://kipublications.ki.se/Default.aspx?queryparsed=id:119722691URI
https://doi.org/10.1136/ard.2009.108035DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

To investigate the effect of tumour necrosis factor (TNF) antagonist treatment on workforce participation in patients with rheumatoid arthritis (RA).Methods:Data from the Stockholm anti-TNFα follow-up registry (STURE) were used in this observational study. Patients with RA (n = 594) aged 18–55 years, (mean (SD) 40 (9) years) followed for up to 5 years were included with hours worked/week as the main outcome measure. Analyses were performed unadjusted and adjusted for baseline age, disease duration, Health Assessment Questionnaire (HAQ), 28-joint Disease Activity Score (DAS28) and pain score.Results:At baseline patients worked a mean 20 h/week (SD 18). In unadjusted analyses, significant improvements in hours worked/week could already be observed in patients at 6 months (mean, 95% CI) +2.4 h (1.3 to 3.5), with further increases compared to baseline at 1-year (+4.0 h, 2.4 to 5.6) and 2-year follow-up (+6.3 h, 4.2 to 8.4). The trajectory appeared to stabilise at the 3-year (+6.3 h, 3.6 to 8.9), 4-year (+5.3 h, 2.3 to 8.4) and 5-year follow-up (+6.6 h, 3.3 to 10.0). In a mixed piecewise linear regression model, adjusted for age, sex, baseline disease activity, function and pain, an improvement of +4.2 h/week was estimated for the first year followed by an added improvement of +0.5 h/week annually during the years thereafter. Over 5 years of treatment, the expected indirect cost gain corresponded to 40% of the annual anti-TNF drug cost in patients continuing treatment.Conclusion:Data from this population-based registry indicate that biological therapy is associated with increases in workforce participation in a group typically expected to experience progressively deteriorating ability to work. This could result in significant indirect cost benefits to society.

Added entries (persons, corporate bodies, meetings, titles ...)

Neovius, MKarolinska Institutet (author)
Cullinane-Carli, C (author)
Eksborg, SKarolinska Institutet (author)
van Vollenhoven, RFKarolinska Institutet (author)
Karolinska Institutet (creator_code:org_t)

Related titles

In:Annals of the rheumatic diseases: BMJ69:1, s. 126-1311468-20600003-4967

Internet link

Find in a library

Annals of the rheumatic diseases (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Augustsson, J; Neovius, M; Cullinane-Carli, ...; Eksborg, S; van Vollenhoven, ...

Articles in the publication: Annals of the rh ...

By the university: Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se